Cero Therapeutics Holdings, INC. (CEROW) — 8-K Filings

All 8-K filings from Cero Therapeutics Holdings, INC.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

8-K Filing — Dec 19, 2025
8-K Filing — Dec 2, 2025
Cero Therapeutics Faces Delisting Notice — Oct 30, 2025 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on October 30, 2025, reporting on events as of October 29, 2025. The filing indicates a notice of delisting or fai
Cero Therapeutics Files 8-K for Material Agreements — Oct 16, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on October 16, 2025, reporting on events that occurred on October 14, 2025. The filing indicates an entry into a m
Cero Therapeutics Files 8-K on Agreements and Equity Sales — Oct 14, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on October 14, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and fi
Cero Therapeutics Holdings Inc. 8-K Filing — Sep 22, 2025 Risk: low
Cero Therapeutics Holdings, Inc. reported on September 22, 2025, that its common stock and warrants are traded on the Nasdaq Capital Market under the symbols CE
Cero Therapeutics Holdings Files 8-K — Sep 5, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The company, formerly known as Phoenix B
Cero Therapeutics Faces Delisting Concerns — Sep 4, 2025 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, f
Cero Therapeutics Files 8-K on Equity Sales — Jul 18, 2025 Risk: medium
On July 18, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report detailing unregistered sales of equity securities. The company, formerly known as Phoenix
Cero Therapeutics Enters Material Definitive Agreement — Jul 14, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. entered into a Material Definitive Agreement on July 11, 2025. The filing also includes financial statements and exhibits relat
Cero Therapeutics to Acquire Private Company — Jul 8, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. announced on July 7, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of a pri
Cero Therapeutics Files 8-K on Key Agreements — Jun 30, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on June 25, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and finan
Cero Therapeutics Files 8-K — Jun 17, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on June 17, 2025, reporting other events and financial statements. The company, formerly known as Phoenix Biotech
Cero Therapeutics Faces Nasdaq Delisting Notice — Jun 13, 2025 Risk: high
Cero Therapeutics Holdings, Inc. announced on June 11, 2025, that it received a notice from Nasdaq regarding its failure to meet continued listing requirements.
Cero Therapeutics Holdings Files 8-K — Jun 11, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on June 11, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial sta
Cero Therapeutics Files 8-K on Equity Sales — Jun 6, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on June 6, 2025, reporting unregistered sales of equity securities and other events. The filing details the compan
Cero Therapeutics Reports Board and Officer Changes — Jun 2, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 30, 2025, reporting changes in its board of directors and executive officers, along with updates to compens
Cero Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes — May 29, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 29, 2025, reporting on several key events. These include the departure of directors or certain officers, th
Cero Therapeutics Holdings Files 8-K — May 8, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 8, 2025, reporting on events as of May 7, 2025. The filing indicates a change in the company's structure or
Cero Therapeutics Files 8-K with Corporate Updates — Apr 25, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on April 25, 2025, reporting events as of April 22, 2025. The filing indicates amendments to its Articles of Incor
Cero Therapeutics Files 8-K: Material Agreements & Equity Sales — Apr 22, 2025 Risk: medium
On April 21, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement,
Cero Therapeutics Files 8-K Report — Feb 12, 2025 Risk: medium
On February 12, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific
Cero Therapeutics Enters Material Definitive Agreement — Feb 6, 2025 Risk: medium
On February 5, 2025, Cero Therapeutics Holdings, Inc. entered into a material definitive agreement. The company, formerly known as Phoenix Biotech Acquisition C
Cero Therapeutics Files 8-K for Other Events — Jan 21, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on January 21, 2025, reporting an event that occurred on January 17, 2025. The filing is categorized under 'Other
Cero Therapeutics Reports Unregistered Equity Sales — Jan 10, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on January 10, 2025, reporting unregistered sales of equity securities that occurred on January 6, 2025. The filin
Cero Therapeutics Holdings, Inc. Files 8-K — Jan 7, 2025 Risk: low
On January 7, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates the company's former name was Phoenix Biotech Acquisition Corp.,
Cero Therapeutics Holdings Files 8-K — Jan 6, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on January 6, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial s
Cero Therapeutics Files 8-K on Equity Sales — Dec 31, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. reported on December 23, 2024, regarding unregistered sales of equity securities and other events. The company, formerly known
Cero Therapeutics Appoints New CMO, CSO, and Directors — Dec 6, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. announced on December 2, 2024, the appointment of Dr. Jonathan G. Y. Chen as Chief Medical Officer and Dr. David M. R. Hall as
Cero Therapeutics Holdings, Inc. Files 8-K — Nov 18, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on November 18, 2024, reporting on events as of November 15, 2024. The filing indicates the company's former name
Cero Therapeutics Files 8-K on Agreements and Shareholder Votes — Nov 12, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on November 12, 2024, reporting on events that occurred on November 8, 2024. The filing indicates the entry into a
Cero Therapeutics Faces Delisting Notice — Nov 1, 2024 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on October 30, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company w
Cero Therapeutics Faces Nasdaq Delisting Warning — Oct 25, 2024 Risk: high
Cero Therapeutics Holdings, Inc. announced on October 24, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued li
Cero Therapeutics Announces CMO Departure, Interim Appointment — Oct 11, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. announced on October 9, 2024, the departure of Dr. Jonathan G. T. Millman as Chief Medical Officer and the appointment of Dr. S
Cero Therapeutics Files 8-K with Corporate Updates — Oct 2, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on September 25, 2024, reporting changes to its articles of incorporation or bylaws, other events, and financial s
Cero Therapeutics to be Acquired by 03 Life Sciences — Sep 26, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. announced on September 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transa
Cero Therapeutics Files 8-K: Agreements, Equity Sales, Officer Changes — Sep 25, 2024 Risk: medium
On September 22, 2024, Cero Therapeutics Holdings, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity
Cero Therapeutics Appoints New CMO, Director — Sep 23, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. announced on September 17, 2024, the appointment of Dr. David J. Earp as Chief Medical Officer and the election of Ms. Sarah E.
Cero Therapeutics Holdings, Inc. Files 8-K — Sep 18, 2024 Risk: low
On September 18, 2024, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates that the company's former name was Phoenix Biotech Acquisition
Cero Therapeutics Holdings Files 8-K — Sep 10, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on September 10, 2024, reporting on other events and financial statements. The company, formerly Phoenix Biotech A
Cero Therapeutics Files 8-K, Updates Business Address — Jul 26, 2024 Risk: low
On July 26, 2024, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 201 Haskins Way, Suit
Cero Therapeutics Faces Delisting Notice — Jul 25, 2024 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on July 25, 2024, reporting a notice of delisting or failure to meet continued listing standards as of July 19, 20
Cero Therapeutics Faces Delisting Notice — May 3, 2024 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on May 3, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The co
Cero Therapeutics Holdings Files 8-K on Security Holder Vote — May 1, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on April 30, 2024, reporting on a submission of matters to a vote of security holders. The company, formerly known
CERO Therapeutics Enters Material Agreement, Sells Equity — Feb 28, 2024 Risk: medium
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an 8-K on February 28, 2024, reporting an event on February 23, 2024, related to an entry into a material definiti
CERO THERAPEUTICS Undergoes Major Corporate Restructuring — Feb 15, 2024 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (formerly Phoenix Biotech Acquisition Corp.) filed an 8-K on February 15, 2024, reporting events as of February 13, 2024. The f
PBAX Enters Material Definitive Agreement — Feb 14, 2024 Risk: medium
Phoenix Biotech Acquisition Corp. (PBAX) filed an 8-K on February 14, 2024, reporting that it entered into a Material Definitive Agreement on February 13, 2024.
PBAX Files 8-K on Shareholder Vote Submission, Other Events — Feb 12, 2024 Risk: medium
Phoenix Biotech Acquisition Corp. (PBAX) filed an 8-K on February 12, 2024, reporting an event that occurred on February 8, 2024, related to the submission of m
PBAX Files 8-K: Material Agreement & Unregistered Equity Sales — Feb 6, 2024
Phoenix Biotech Acquisition Corp. (PBAX) filed an 8-K on February 5, 2024, indicating an entry into a material definitive agreement and unregistered sales of eq
PBAX Files 8-K on Rule 425 Communications, Signaling Deal Progress — Jan 5, 2024
Phoenix Biotech Acquisition Corp. (PBAX) filed an 8-K on January 5, 2024, reporting an event on January 3, 2024, related to written communications under Rule 42

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX